Progenra, Inc. is a leader in the discovery and development of a new class of medicine called Molecular Glues. Molecular glues induced proximity, an emerging form of therapeutics that functions by bringing two proteins into contact with each other.

Progenra exploits the ubiquitin proteasome system for drug development by harnessing ubiquitin ligases to induce target protein degradation (TPD).

Our UbiPro™ Drug Discovery Platform is a multi-faceted approach based on the physiological milieu in which enzymes of the ubiquitin proteasome system interact with their substrates.

This approach has led to breakthroughs in developing drug candidates for evaluation and progression in different therapeutic areas.